Venous Thromboembolism in Patients With Autoimmune Disorders: Findings From the RIETE Registry.
Ficheros
Estadísticas
Métricas y Citas
Metadatos
Mostrar el registro completo del ítemFecha
2020Departamento/s
MedicinaFuente
Angiology. 2020 Feb;71(2):131-138.Resumen
Patients with autoimmune disorders are at an increased risk of venous thromboembolism (VTE), but this association has not been
consistently evaluated. We used the RIETE (Registro Informatizado Enfermedad Trombo Embo ́ lica) database to compare the
rates of VTE recurrences, major bleeding, and death during the course of anticoagulation, according to the presence or absence of
autoimmune disorders. Of 71 625 patients with VTE recruited in February 2018, 1800 (2.5%) had autoimmune disorders. Median
duration of anticoagulant therapy was slightly longer in patients with autoimmune disorders (median, 190 vs 182 days; P ¼ .001).
On multivariable analysis, patients with autoimmune disorders had a similar risk of VTE recurrences (hazard ratio [HR]: 0.93; 95%
confidence interval [CI]: 0.68-1.27) or major bleeding (HR: 1.07; 95% CI: 0.82-1.40) and a lower risk to die (HR: 0.66; 95% CI:
0.54-0.81) than those without autoimmune disorders. Patients with giant cell arteritis had the highest rates of major bleeding (8.6
events per 100 patient-years) and the lowest rate of recurrences (zero). In other subgroups, the rates of both events were more
balanced. During anticoagulation, patients with or without autoimmune disorders had similar rates of VTE recurrences or major
bleeding. However, there were some differences between subgroups of patients with autoimmune disorders.
Materias
autoimmune disorders; venous thromboembolism; bleeding; recurrences; anticoagulant therapyColecciones
- Artículos Científicos [12009]





